Introduction: Obstructive Sleep Apnea Syndrome (OSAS) is associated with clinical pictures ranging from morning headache to vascular diseases and sudden death. It negatively affects the quality of life by causing deterioration in sleep quality, a decrease in work and academic performance caused by excessive daytime sleepiness (EDS), social restriction, and an increase in work/traffic accidents and depression. OSAS may cause comorbidities and conditions by desaturation. We aimed to investigate the effect of desaturation and cellular level hypoxia in patients with OSAS on comorbid diseases and conditions and emphasize their importance. Subjects and Methods: The study design was cross-sectional. A total of 100 patients (73 males and 27 females) aged 18–70 years were included in the study. Demographic data, presence of comorbidities (diabetes mellitus [DM], hypertension [HT], coronary artery disease), and symptoms related to OSAS (nocturia, enuresis, and morning headache) were questioned. In addition, the Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Scale were administered, the results of polysomnographic data were evaluated, and lactic acid levels were measured as an indicator of hypoxia at the cell level. Results: The minimum oxyhemoglobin saturation level was found to be associated with body mass index (BMI) (P = 0.004), HT (P = 0.005), ESS scores (P = 0.022), sleep apnea severity, depression scale (P = 0.012), position-related sleep apnea (P = 0.005), and lactic acid levels (P = 0.002). No correlation was found between sex, DM, CAD, morning headache, nocturia and enuresis, PSQI, and repaid eye movement -related sleep apnea. Conclusion: Although hypoxemia was shown to be associated with BMI, HT, EDS, depression, sleep apnea severity, positional apnea, and lactic acid in our study, sufficient evidence could not be obtained to consider the minimum oxyhemoglobin saturation level in the OSAS treatment plan. In the clinical evaluation of OSAS, apnea-hypopnea index and these parameters should be taken into account by physicians in the prediction of comorbidities and risks.
The presence of oligoclonal bands in cerebrospinal fluid of multiple sclerosis patients is now well established to support the clinical diagnosis. On the other hand, a single band response can represent the initial stage of an oligoclonal response, before the other antibody clones become visible. Method: The aim of the current study was to evaluate the presence of an isolated cerebrospinal fluid single immunoglobulin band, and to analyse the clinical and radiological diagnosis of the samples with a single immunoglobulin band. In this study, 3524 cerebrospinal fluid samples were re-examined using agarose gel isoelectric focusing, and ones with an isolated cerebrospinal fluid immunoglobulin band were detected. Results: A single band in cerebrospinal fluid was detected in 1.4% samples. A clinically isolated syndrome was diagnosed in 27.5%of them, relapsing remitting multiple sclerosis in 49%, secondary progressive multiple sclerosis in 11.8%, and radiologically isolated syndrome in 2%. No primary progressive multiple sclerosis patient was found. All Barkhoff criteria were met in 90.1% of them. The remaining were diagnosed with other inflammatory neurological diseases (9.8%). Conclusion: The presence of an isolated cerebrospinal fluid monoclonal immunoglobulin band is rare. Although most of the samples were diagnosed as multiple sclerosis according to both clinical and paraclinical (magnetic resonance imaging) parameters, they had only a single immunoglobulin band in cerebrospinal fluid. Not only oligoclonal bands, but also an isolated cerebrospinal fluid single band might be a cornerstone for the diagnosis of multiple sclerosis at least for some patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.